Therefore, concurrent monitoring of adefovir and OAT1/3 endogenous biomarker, such as PDA, would enable the assessment of a range of OAT1 inhibitory potencies, as well as the clinical significance of the interaction on highly and weakly protein‐bound OAT1 substrates. The gene discussed is SLC22A6; the disease is Patent ductus arteriosus.